Abstract

The Southwest Oncology Group (SWOG) is one of several cooperative groups involved in the clinical investigation of cancer. Multiple modalities including surgery, radiation therapy and chemotherapy are routinely combined in protocols to evaluate the effect of different treatment regimens on specific diseases. The specific objectives of SWOG study include reducing toxicity of treatment, improving host resistance to neoplasm, and improving the responsiveness to a disease of treatment.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA020319-16
Application #
3556497
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1978-01-01
Project End
1992-12-31
Budget Start
1992-01-01
Budget End
1992-12-31
Support Year
16
Fiscal Year
1992
Total Cost
Indirect Cost

  Institution

Name
Swedish Medical Center, First Hill
Department
Type
DUNS #
City
Seattle
State
WA
Country
United States
Zip Code
98122

  Publications

Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Sala Torra, Olga; Othus, Megan; Williamson, David W et al. (2017) Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients. Biol Blood Marrow Transplant 23:691-696
Haas, Naomi B; Manola, Judith; Uzzo, Robert G et al. (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387:2008-16
Othus, M; Mukherjee, S; Sekeres, M A et al. (2016) Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course. Leukemia 30:1779-80
Cesano, Alessandra; Willman, Cheryl L; Kopecky, Kenneth J et al. (2015) Cell signaling-based classifier predicts response to induction therapy in elderly patients with acute myeloid leukemia. PLoS One 10:e0118485
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-440
Persky, Daniel O; Miller, Thomas P; Unger, Joseph M et al. (2015) Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood 125:236-41
Flaherty, Keith T; Manola, Judith B; Pins, Michael et al. (2015) BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN C J Clin Oncol 33:2384-91
Ostronoff, Fabiana; Othus, Megan; Lazenby, Michelle et al. (2015) Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report. J Clin Oncol 33:1157-64
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62

Showing the most recent 10 out of 301 publications